{"disease":{"id":"brca-mutated-ovarian-carcinoma","name":"brca mutated ovarian carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04009148","title":"Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT03943173","title":"Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06065059","title":"Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Tango Therapeutics, Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}